Leveraging computational tools to understand the triptolide-XPB interaction

David Gorrie
DOI: https://doi.org/10.1101/2024.12.07.627336
2024-12-10
Abstract:Triptolide is a natural product isolated from a traditional Chinese medicinal plant for treating rheumatoid arthritis and other autoimmune diseases. Triptolide displays diverse bioactivities, including anti-inflammation, immunosuppression, anti-cancer, etc. Triptolide was reported to crosslink with the residue Cys342 of human XPB (HsXPB), a DNA helicase required for transcription and DNA repair. This interaction inhibits XPB's ATPase activity. Here, we report that triptolide specifically inhibits the ATPase activity of HsXPB but has no impact on its archaeal homo-logs, indicating that triptolide's effect on HsXPB is not conserved among XPB homologs. Computational docking further confirmed this, which showed that the predicted triptolide binding sites have different distribution patterns among HsXPB and its archaeal homologs. Computational modeling revealed that crosslinking of triptolide with Cys342 of HsXPB allows triptolide to occupy the positions of the beta- and gamma-phosphate of adenosine triphosphate (ATP) at the ATP binding site, therefore providing a barrier to ATP binding and hydrolysis by HsXPB.
Biochemistry
What problem does this paper attempt to address?